Exopeptidase profiles of bifidobacteria.

Abstract

SummaryThe exopeptidase activities of five different strains of bifi dobacteria occurring habitually in healthy human intestinal canal were measured on 61 synthetic substrates. The cluster analysis, based on the results, indicates that four strains, with the exception of Bifidobacterium adolescentis a M101-4, have similar exopeptidase profiles. All CFE from these five strains contained at least three kinds of aminopeptidases (aminopeptidase with broad substrate specificity, amino peptidase hydrolyzing selectively X-Pro type and aminopeptidase hy drolyzing selectively Pro-X type) and carboxypeptidase.

High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan

“…Gut microbiota, especially Bifidobacterium, produce peptidases that may metabolize linaclotide. 25 GC-C gene polymorphism 26 and GUCA2A gene polymorphism 27 are actually present. Therefore, a differential combination of these factors may explain the difference.…”

“…Given these background factors, individual differences in the efficacy of linaclotide may be dependent on catabolism of linaclotide, GC‐C gene polymorphism, GUCA2A gene polymorphism, and/or dietary factors. Gut microbiota, especially Bifidobacterium, produce peptidases that may metabolize linaclotide . GC‐C gene polymorphism and GUCA2A gene polymorphism are actually present.…”

Dose‐finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double‐blind, and placebo‐controlled study

“…Diet may interfere with digestion of the polypeptide linaclotide . Gut microbiota, especially Bifidobacterium, produce peptidases that may metabolize linaclotide . There are known differences in genetic polymorphism among different populations .…”

Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double‐blind, placebo‐controlled study

“…The disulfide bonds of both peptides are reduced in the small intestine, where they are subsequently proteolyzed and degraded . Actually, Japanese have more abundant Bifidobacteria than other nations and many Bifidobacteria have exopeptidase . Therefore, a difference in endogenous or bacterial proteases might also help to explain 0.5 mg/day as the optimal dose for IBS‐C patients in Japan.…”